These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
402 related articles for article (PubMed ID: 19104813)
1. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Guan J; Lo M; Dockery P; Mahon S; Karp CM; Buckley AR; Lam S; Gout PW; Wang YZ Cancer Chemother Pharmacol; 2009 Aug; 64(3):463-72. PubMed ID: 19104813 [TBL] [Abstract][Full Text] [Related]
2. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Doxsee DW; Gout PW; Kurita T; Lo M; Buckley AR; Wang Y; Xue H; Karp CM; Cutz JC; Cunha GR; Wang YZ Prostate; 2007 Feb; 67(2):162-71. PubMed ID: 17075799 [TBL] [Abstract][Full Text] [Related]
3. Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Narang VS; Pauletti GM; Gout PW; Buckley DJ; Buckley AR Anticancer Res; 2003; 23(6C):4571-9. PubMed ID: 14981898 [TBL] [Abstract][Full Text] [Related]
4. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Chen RS; Song YM; Zhou ZY; Tong T; Li Y; Fu M; Guo XL; Dong LJ; He X; Qiao HX; Zhan QM; Li W Oncogene; 2009 Jan; 28(4):599-609. PubMed ID: 19015640 [TBL] [Abstract][Full Text] [Related]
5. Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Narang VS; Pauletti GM; Gout PW; Buckley DJ; Buckley AR Chemotherapy; 2007; 53(3):210-7. PubMed ID: 17356269 [TBL] [Abstract][Full Text] [Related]
6. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo. Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725 [TBL] [Abstract][Full Text] [Related]
7. Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc- protects from oxidative glutamate toxicity. Lewerenz J; Klein M; Methner A J Neurochem; 2006 Aug; 98(3):916-25. PubMed ID: 16771835 [TBL] [Abstract][Full Text] [Related]
8. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma. Budak-Alpdogan T; Chen B; Warrier A; Medina DJ; Moore D; Bertino JR Clin Cancer Res; 2009 Feb; 15(4):1232-40. PubMed ID: 19174488 [TBL] [Abstract][Full Text] [Related]
9. High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells. Thomas AG; Sattler R; Tendyke K; Loiacono KA; Hansen H; Sahni V; Hashizume Y; Rojas C; Slusher BS PLoS One; 2015; 10(8):e0127785. PubMed ID: 26252954 [TBL] [Abstract][Full Text] [Related]
10. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer. Zhou J; Chen J; Mokotoff M; Zhong R; Shultz LD; Ball ED Clin Cancer Res; 2003 Oct; 9(13):4953-60. PubMed ID: 14581370 [TBL] [Abstract][Full Text] [Related]
11. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059 [TBL] [Abstract][Full Text] [Related]
12. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Huang Y; Dai Z; Barbacioru C; Sadée W Cancer Res; 2005 Aug; 65(16):7446-54. PubMed ID: 16103098 [TBL] [Abstract][Full Text] [Related]
13. Burn injury induces the expression of cystine/glutamate transporter (x(c)(-)) in mouse T cells. D'Elia M; Patenaude J; Dupras C; Bernier J Immunol Lett; 2009 Aug; 125(2):137-44. PubMed ID: 19576933 [TBL] [Abstract][Full Text] [Related]
14. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Onn A; Isobe T; Itasaka S; Wu W; O'Reilly MS; Ki Hong W; Fidler IJ; Herbst RS Clin Cancer Res; 2003 Nov; 9(15):5532-9. PubMed ID: 14654533 [TBL] [Abstract][Full Text] [Related]
15. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Song P; Sekhon HS; Lu A; Arredondo J; Sauer D; Gravett C; Mark GP; Grando SA; Spindel ER Cancer Res; 2007 Apr; 67(8):3936-44. PubMed ID: 17440109 [TBL] [Abstract][Full Text] [Related]
16. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes. Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038 [TBL] [Abstract][Full Text] [Related]
18. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. Lo M; Wang YZ; Gout PW J Cell Physiol; 2008 Jun; 215(3):593-602. PubMed ID: 18181196 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of xc⁻ transporter-mediated cystine uptake by sulfasalazine analogs. Shukla K; Thomas AG; Ferraris DV; Hin N; Sattler R; Alt J; Rojas C; Slusher BS; Tsukamoto T Bioorg Med Chem Lett; 2011 Oct; 21(20):6184-7. PubMed ID: 21889337 [TBL] [Abstract][Full Text] [Related]
20. Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. Kuo TH; Kubota T; Watanabe M; Furukawa T; Kase S; Tanino H; Saikawa Y; Ishibiki K; Kitajima M; Hoffman RM Anticancer Res; 1993; 13(3):627-30. PubMed ID: 8391244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]